meta:
  schema_version: '1.0'
  compatible_engine: cellswarm>=2.0
combination_id: durva_treme
components:
- durvalumab
- tremelimumab
clinical_trial: POSEIDON
indication: NSCLC
interaction_model: bliss_independence
synergy_rules:
  CD8_T:
    synergy_factor: 1.35
    affected_parameters:
    - activation
    - exhaustion
    notes: PD-L1 + CTLA-4 dual blockade
  Tumor:
    synergy_factor: 1.2
    affected_parameters:
    - immune_evasion
  Treg:
    synergy_factor: 1.3
    affected_parameters:
    - suppressive_activity
    notes: Tremelimumab depletes Tregs
  Macrophage:
    synergy_factor: 1.15
    affected_parameters:
    - polarization
  NK:
    synergy_factor: 1.15
    affected_parameters:
    - activation
  B_cell:
    synergy_factor: 1.05
    affected_parameters:
    - activation
toxicity_interaction:
  irAE_probability: 0.4
  dose_adjustment: 0.8
cancer_specific_modifiers:
  TNBC:
    efficacy_modifier: 0.5
    notes: Not standard
  Melanoma:
    efficacy_modifier: 0.8
    notes: Nivo+Ipi preferred
  NSCLC:
    efficacy_modifier: 1.1
    notes: 'POSEIDON: Durva+Treme+chemo'
  CRC-MSI-H:
    efficacy_modifier: 0.8
    notes: Dual ICI rationale
  CRC-MSS:
    efficacy_modifier: 0.2
    notes: Ineffective
  Ovarian:
    efficacy_modifier: 0.4
    notes: Limited data
references:
- description: 'POSEIDON: Durva+Treme+chemo in NSCLC. Johnson et al. J Clin Oncol 2023'
  pmid: '36327426'
  verified: true
